Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
engineered Lactobacillus reuteri (Shenzhen People's Hospital)
- Development stage
- Phase 2
- Lead developer
- Shenzhen People's Hospital
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
Engineered Lactobacillus reuteri (MPN-coated) is a topical live biotherapeutic product (LBP) developed by Shenzhen People’s Hospital for the treatment of acne vulgaris. The therapy consists of a genetically modified strain of *Lactobacillus reuteri* designed to modulate the skin microbiome and potentially deliver therapeutic factors to the site of infection. To enhance stability and efficacy, the bacteria are encapsulated in a metal-phenolic network (MPN) coating composed of zinc sulfate and tannic acid. This coating provides additional antimicrobial and anti-inflammatory properties, protecting the probiotic from environmental degradation while synergistically targeting *Cutibacterium acnes* and reducing skin inflammation. The drug is currently being evaluated in clinical trials as a topical cream.
- Other names
- engineered Lactobacillus reuteri (MPN-coated)MPN-coated engineered Lactobacillus reuterizinc sulfate–tannic acid coated engineered Lactobacillus reuteri
Beyond the preview
Go deeper on engineered Lactobacillus reuteri (Shenzhen People's Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on engineered Lactobacillus reuteri (Shenzhen People's Hospital).